BIOSS: results of the new drug-eluting stent for bifurcations

This new device is a stainless steel platform of 120 µm thick with a sirolimus-eluting bio-absorbable polymer. It has two separate parts: a larger diameter proximal part and a smaller diameter distal part connected by two 1.2 mm structures. The objective of this study was to test (first in man) the device in bifurcations. We performed a prospective study of 60 patients with bifurcation lesions. The primary endpoint of the study were the major events (MACE) after one year. The secondary endpoint was the performance of the device, the angiographic parameters after 12 months and the safety. 

21.7% of the population were patients with acute coronary syndrome and 38.3% of had diabetes, this being a high-risk population for a study of this nature. More than half of the patients (52%) had lesions that compromised the whole bifurcation (Medina 1,1,1). Late lumen loss at 12 months was 0.26 mm for the proximal vessel, 0.22 for the distal vessel and 0.09 mm for the side branch, with only 3 patients (6.4%) undergoing a lesion revascularization. All of them had focal restenosis of the device. 

Conclusion: This device can be a quick and easy alternative for treating bifurcations with a single stent.

Robert J. Gil, MD.
2013-05-22

Original title: Dedicated bifurcation sirolimus-eluting stent BIOSS Lim registry: the first-in-man study.

More articles by this author

REPRISE II: results obtained with the new valve according to VARC criteria

The objective was to evaluate the safety and efficacy of the Lotus Valve System to treat patients with severe aortic stenosis and high surgical...

DEFLECT I: cerebral protection device in TAVI

Strokes after TAVI occur in between 3.8 and 6.7% of the cases, with new MRI lesions being almost the rule. The TriGuard EDD device...

DISCOVER: new low profile valve with little post-implant regurgitation

The objective of the study was to assess events after 30 days with the DirectFLOW Medical Valve device in patients with severe aortic stenosis...

JUPITER: transapical TAVI device

We evaluated 88 consecutive patients (at this phase) with severe aortic stenosis who received the second-generation device for transapical access. Survival at thirty days...

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Related Articles

SOLACI Sessionsspot_img

Recent Articles

Patients at High Risk of Bleeding After Coronary Angioplasty: Are Risk Assessment Tools ARC-HBR and PRECISE-DAPT Useful?

Patients undergoing coronary stenting typically receive dual antiplatelet therapy (DAPT) for 6 to 12 months, consisting of a P2Y12 receptor inhibitor and aspirin. While DAPT...

ACC 2025 | WARRIOR: Ischemia in Women with Non-Obstructive Coronary Artery Disease

Approximately half of all women with symptomatic ischemia who undergo coronary angiography are found to have non-obstructive coronary artery disease ((ischemia and non-obstructive coronary...

ACC 2025 | TAVI in Low-Risk Patients: 5-Year Outcomes of EVOLUTE LOW RISK

Transcatheter aortic valve implantation (TAVI) is a valid alternative to surgery in low-risk patients with severe aortic stenosis. However, one of its main limitations...